Abstract: SS31 peptide, a mitochondrial-targeted antioxidant, demonstrates breakthrough efficacy in 2026 research for mitochondrial dysfunction disorders. Composed of D-arginine and aromatic residues, it enhances ATP production and reduces oxidative stress. Industry growth is driven by expanding applications in neurodegenerative and metabolic diseases. Comparative studies show superior mitochondrial uptake over MitoQ. Selection guidelines prioritize purity (>98%) and stability. Emerging data supports its therapeutic potential, positioning SS31 as a key player in mitochondrial therapy innovation.
Target Keyword: ss 31
SS31 peptide, also known as Mito-DNP or D-Arg-2',6'-Dmt-Lys-Phe-NH2, is a synthetic tetrapeptide specifically engineered for mitochondrial targeting. Its molecular formula is C34H52N10O5, with a molecular weight of approximately 680.84 g/mol. The peptide is composed of D-arginine, 2',6'-dimethyltyrosine (Dmt), lysine, and phenylalanine, which confer both stability and selective mitochondrial membrane penetration. For B2B buyers, the standard purity threshold is ≥98% as verified by HPLC, with solubility in water or DMSO at concentrations up to 10 mg/mL. Storage conditions require lyophilized powder at -20°C, protected from light and moisture, ensuring a shelf life of 24 months. Key technical indicators include a net positive charge at physiological pH, enabling electrostatic interaction with cardiolipin on the inner mitochondrial membrane, and a partition coefficient (logP) of approximately 1.2, balancing hydrophilicity and lipophilicity for optimal cellular uptake.
Industry data from 2026 indicates that the global mitochondrial-targeted peptide market, driven by SS31 peptide, is projected to reach $1.2 billion by 2030, with a compound annual growth rate (CAGR) of 14.5%. This growth is fueled by expanding applications in neurodegenerative disease research and metabolic disorder studies, where SS31 peptide demonstrates superior mitochondrial uptake and ATP enhancement compared to conventional antioxidants.
The production of SS31 peptide employs solid-phase peptide synthesis (SPPS) using Fmoc chemistry, ensuring precise amino acid sequence assembly. Each batch undergoes a multi-step purification process, including reversed-phase high-performance liquid chromatography (RP-HPLC) to achieve ≥98% purity. Quality control protocols are rigorous, with third-party testing for identity, purity, and bioactivity. Every shipment includes a Certificate of Analysis (CoA) detailing HPLC chromatograms, mass spectrometry (MS) confirmation, and endotoxin assays. For B2B buyers, additional certifications such as ISO 9001:2015 for manufacturing facilities and GMP compliance for research-grade peptides are standard. The manufacturing process is designed to minimize batch-to-batch variability, with a typical yield of 85-90% from crude peptide to final lyophilized product.
SS31 peptide is utilized across diverse B2B sectors, including cosmetic formulation, laboratory research, and bulk wholesale distribution. In cosmetic formulations, it is incorporated into anti-aging serums and creams at concentrations of 0.1-1.0%, targeting mitochondrial dysfunction in skin cells to reduce oxidative stress and improve cellular energy. For laboratory research, SS31 peptide is a standard tool in studies of mitochondrial dysfunction, neurodegenerative diseases (e.g., Parkinson's, Alzheimer's), and metabolic disorders, with typical dosages of 1-10 µM in cell culture or 1-5 mg/kg in animal models. Bulk wholesale buyers, such as peptide distributors and contract research organizations (CROs), purchase SS31 peptide in quantities ranging from 1 gram to 1 kilogram, with custom packaging and labeling options. The peptide's stability and high purity make it ideal for long-term storage and multi-site research projects.
| Item | Our Product (SS31 Peptide) | Alternatives (Low-Grade Peptides) | Advantages |
|---|---|---|---|
| Purity | ≥98% by HPLC | Often <90% with impurities | Higher purity ensures consistent research results and reduced batch variability. |
| Stability | 24 months at -20°C | 6-12 months due to degradation | Extended shelf life reduces waste and storage costs for bulk buyers. |
| Mitochondrial Uptake | 1000-fold higher than untargeted antioxidants | Low or non-specific uptake | Superior targeting enhances efficacy in mitochondrial dysfunction studies. |
| Endotoxin Levels | <0.1 EU/mg | Often >1 EU/mg | Low endotoxins ensure suitability for in vivo research without immune interference. |
| Cost Performance | Competitive pricing with bulk discounts | Lower upfront cost but higher failure rates | Higher purity and stability reduce overall research costs and improve data reliability. |
When purchasing SS31 peptide in bulk, B2B buyers must avoid common pitfalls such as accepting low-purity products, neglecting stability data, or overlooking third-party testing. Selection standards should prioritize suppliers with ISO 9001:2015 certification and GMP compliance, ensuring consistent quality across batches. A buyer checklist includes verifying purity via HPLC chromatograms, confirming molecular weight via MS, and requesting endotoxin and heavy metal test results. Additionally, consider the supplier's lead time, packaging options (e.g., vacuum-sealed vials or bulk containers), and technical support for formulation or research applications. For long-term projects, negotiate bulk discounts and secure a minimum of three batch-specific CoAs to ensure reproducibility.
SS31 peptide offers distinct advantages for B2B buyers, including high purity (≥98%), exceptional stability (24 months at -20°C), and cost performance with bulk discounts. The peptide's mitochondrial-targeted design ensures superior uptake and efficacy in research applications, reducing the need for high dosages and minimizing off-target effects. Technical support from suppliers includes formulation guidance, assay protocols, and custom packaging options, enabling seamless integration into research or product development workflows. For bulk buyers, the combination of quality, stability, and support translates to lower total cost of ownership and higher data reliability.
Q: What is the recommended storage condition for SS31 peptide to maintain its stability?
A: SS31 peptide should be stored as a lyophilized powder at -20°C, protected from light and moisture. Under these conditions, it remains stable for up to 24 months. Reconstituted solutions in water or DMSO should be used within 7 days when stored at 4°C to prevent degradation.
Q: How does SS31 peptide compare to MitoQ in terms of mitochondrial uptake and efficacy?
A: SS31 peptide demonstrates superior mitochondrial uptake compared to MitoQ, with a 1000-fold higher accumulation in mitochondria due to its selective binding to cardiolipin. In comparative studies, SS31 peptide shows enhanced ATP production and reduced oxidative stress, making it more effective for research into mitochondrial dysfunction disorders.
Q: What purity level is required for SS31 peptide in research applications?
A: For reliable research results, SS31 peptide should have a purity of at least 98% as verified by HPLC. Higher purity (99%+) is recommended for in vivo studies or sensitive assays, as impurities can introduce variability and compromise data integrity. Always request a Certificate of Analysis from the supplier to confirm purity.